The price of Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares last traded on Wall Street fell -6.17% to $0.54.
Based on available information, 4 analysts follow Inovio Pharmaceuticals Inc. (NASDAQ:INO). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $2.00 and a low of $1.00, we find $1.50. Given the previous closing price of $0.58, this indicates a potential upside of 158.62 percent. INO stock price is now -5.70% away from the 50-day moving average and -57.94% away from the 200-day moving average. The market capitalization of the company currently stands at $151.82M.
Among analysts, 4 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $1.50 as their price target over the next twelve months.
In other news, Zoth Lota S., Director sold 5,700 shares of the company’s stock on Jun 05. The stock was sold for $3,192 at an average price of $0.56. Upon completion of the transaction, the Director now directly owns 52,716 shares in the company, valued at $28466.64. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 13, Director Weiner David B. sold 5,833 shares of the business’s stock. A total of $6,708 was realized by selling the stock at an average price of $1.15. This leaves the insider owning 910,124 shares of the company worth $0.49 million. Insiders disposed of 253,161 shares of company stock worth roughly $0.14 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in INO stock. A new stake in Inovio Pharmaceuticals Inc. shares was purchased by JACOBS LEVY EQUITY MANAGEMENT, INC during the first quarter worth $636,000. PROFUND ADVISORS LLC invested $226,000 in shares of INO during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in Inovio Pharmaceuticals Inc. valued at approximately $213,000. CANDRIAM S.C.A. acquired a new stake in INO for approximately $205,000. SHELL ASSET MANAGEMENT CO purchased a new stake in INO valued at around $89,000 in the second quarter. In total, there are 256 active investors with 47.80% ownership of the company’s stock.
During the past 12 months, Inovio Pharmaceuticals Inc. has had a low of $0.38 and a high of $2.82. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 4.20, and a quick ratio of 4.20. The fifty day moving average price for INO is $0.5670 and a two-hundred day moving average price translates $1.2780 for the stock.
The latest earnings results from Inovio Pharmaceuticals Inc. (NASDAQ: INO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.16, missing analysts’ expectations of -$0.14 by -0.02. This compares to -$0.36 EPS in the same period last year. The company reported revenue of $0.12 million for the quarter, compared to $0.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.21 percent. For the current quarter, analysts expect INO to generate $260k in revenue.
Inovio Pharmaceuticals Inc.(INO) Company Profile
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
